title: Cisplatin combined with carboplatin: a new way of intensification of platinum dose in the treatment of advanced ovarian cancer. Belgian Study Group for Ovarian Carcinoma.
abstract: We performed a phase I-II trial of escalating doses of cisplatin (CDDP: 50-100 mg/m2 per course) plus carboplatin (CBDCA: 300-400 mg/m2 per course) as a potential way in which to maximize platinum doses without causing excessive toxic effects in patients with advanced ovarian cancer. Thirty-three patients with nonoptimally debulked disease of FIGO (International Federation of Gynecology and Obstetrics) stages IIc-IV [median age: 60 yr; median WHO (World Health Organization) performance status: 2; no prior chemotherapy] received a median of six courses of therapy. CBDCA was infused on day 1 and CDDP on day 2 with an aggressive 48-hour hydration regimen. Myelosuppression was dose-limiting: at the highest dose levels, WHO grade 4 neutropenia and thrombocytopenia led to dose reduction and/or treatment delay in 45% of the patients. Nonhematologic toxic effects included acute nausea and vomiting (97% of the patients), mild alopecia (45%), ototoxic effects (39%), neurotoxic effects (21%), and renal toxic effects (serum creatinine greater than 1.5 mg/dL: 12.5%). The pathologic complete response rate was 22%. We conclude that CBDCA and CDDP can be given safely in combination at reasonably high doses (CBDCA at 300 mg/m2 per course and CDDP at 100 mg/m2 per course) over a 6-month period, provided a close hematologic follow-up is conducted. Randomized clinical trials are needed to define whether this regimen is any better than standard combination chemotherapy.
authors.affiliation: Service de Médecine, Institut Jules Border, Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels, Belgium.
authors.forename: M J
authors.initials: MJ
authors.lastname: Piccart
authors.forename: J M
authors.initials: JM
authors.lastname: Nogaret
authors.forename: L
authors.initials: L
authors.lastname: Marcelis
authors.forename: H
authors.initials: H
authors.lastname: Longrée
authors.forename: F
authors.initials: F
authors.lastname: Ries
authors.forename: J P
authors.initials: JP
authors.lastname: Kains
authors.forename: P
authors.initials: P
authors.lastname: Gobert
authors.forename: A M
authors.initials: AM
authors.lastname: Domange
authors.forename: J P
authors.initials: JP
authors.lastname: Sculier
authors.forename: C
authors.initials: C
authors.lastname: Gompel
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects; D016190:Carboplatin; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D010051:Ovarian Neoplasms / Q000188:drug therapy*
chemical_list: D009944:Organoplatinum Compounds; D016190:Carboplatin; D002945:Cisplatin